May 2, 2018 09:25 AM EDTUpdated 10:26 AM

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

Amber Tong

J&J $JNJ is bringing a low-profile biotech — and some early-stage oncolytic viruses — into its fold, cementing its immuno-oncology pipeline with some nascent technologies that it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

Amber Tong

Sign up to read this article for free.

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Play­ing the long game in I/O, J&J inks $1.04B deal to buy on­colyt­ic virus plat­form biotech BeneVir

Amber Tong

Sign up to read this article for free.

more like this

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

Amgen’s once-a-month obesity shot shows 20% weight loss after a year

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial